Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method

doi:10.5246/jcps.2023.05.035

Abstract

Abstract:

In the present study, we aimed to investigate the availability and affordability of osteoporosis (OP) treatment drugs in Wuhan and provide references for policymakers. We used the WHO/HAI standardization method to investigate the OP drug in Wuhan and collected drug information for statistical analysis to evaluate the availability and affordability. The results showed that the availability of bisphosphonates, active vitamin D, and their analogs was relatively high; the availability of denosumab, salmon calcitonin, and teriparatide was general; and the availability of calcitonin, raloxifene, and strontium ranelate was low. In terms of affordability, alendronate generic drugs had good affordability, while the other 10 OP treatment drugs had poor affordability. Generally, the overall availability of OP treatment drugs in Wuhan was average, and the affordability was poor. As China’s aging problem intensified, relevant government departments might consider including more OP treatment drugs in the medical insurance catalog and concentrating their quantities in the procurement process to further improve the availability and affordability of OP treatment drugs.

Key words: WHO/HAI, Osteoporosis treatment drugs, Availability, Affordability

Supporting:

Min Wan, Jinyu Liu, Guangyi Yu, Suiju Tong, Lei Ke, Yu Zhang, Ruxu You. Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 417-425.

Figures/Tables 6

Table 1. Specifications and dosage forms of 11 OP treatment drugs.

Table 2. The availability of OP treatment drugs (%).

Table 3. The availability of OP treatment drugs in public medical institutions and retail pharmacies (n = 11).

Table 4. Affordability of OP treatment drugs (unit: times).

Table 5. Comparison of the overall affordability of OP treatment drugs in public hospitals and retail pharmacies.

Table 6. Comparison of overall affordability of OBs and LPGs.

References 24

[1]	Consensus development conference: prophylaxis and treatment of osteoporosis. Am. J. Med. 1991, 90, 107–110.
[2]	NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South. Med. J. 2001, 94, 569–573.
[3]	Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017). Chin. J. Osteoporos. 2019, 25, 281–309.
[4]	Si, L.; Winzenberg, T.M.; Jiang, Q.; Chen, M.; Palmer, A.J. Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int. 2015, 26, 1929–1937.
[5]	National Bureau of Statistics of the People's Republic of China. China Statistical Yearbook. Beijing: China Statistics Press. 2020.
[6]	Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis. Chin. J. Osteoporos. 2019, 25, 281–309.
[7]	Kheder, S.; Ali, H.M. Medicine prices, availability, affordability and price components in Sudan. World Health Organization. 2014.
[8]	Zhang, Y.; Li, X. Investigation and analysis of availability and affordability of essential medicine in Nanjing based on WHO/HAI standard survey method. China Pharm. 2015, 26, 4188–4192.
[9]	Wang, X.; Yang, S.M.; Fang, Y.; Jiang, M.H.; Wu, L.N. Study on the availability and price of pediatric essential medicines in public hospitals in Shaanxi Province using WHO/HAI methodology. China Pharm. 2014, 25, 681–684.
[10]	Dong, Z.J.; Tao, Q.C.; Yan, B.B.; Sun, G.J. Availability, prices and affordability of essential medicines in Zhejiang Province, China. PLoS One. 2020, 15, e0241761.
[11]	Gong, S.W.; Cai, H.B.; Ding, Y.F.; Li, W.J.; Juan, X.; Peng, J.L.; Jin, S. The availability, price and affordability of antidiabetic drugs in Hubei Province, China. Health Policy Plan. 2018, 33, 937–947.
[12]	Department of Human Resources and Social Security of Hubei Province. Circular of the General Office of the Provincial People’s Government on Adjusting the Provincial Minimum Wage Standard. 2021 [EB/OL]. (2021-08-31). This article can be found online at http://www.hubei.gov.cn/zxjy/rdhy/202108/t20210831_3730793.shtml.
[13]	You, R.; Liu, Z. Economic evaluation of oral alendronate therapy for osteoporosis in Chinese postmenopausal women: the impact of medication compliance and persistence. Front. Pharmacol. 2020, 11, 575893.
[14]	You, R.; Zhang, Y.; Wu, D.B.; Liu, J.; Qian, X.; Luo, N.; Mori, T. Cost-effectiveness of zoledronic acid versus oral alendronate for postmenopausal osteoporotic women in China. Front. Pharmacol. 2020, 11, 456.
[15]	Eastell, R.; Rosen, C.J.; Black, D.M.; Cheung, A.M.; Murad, M.H.; Shoback, D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society. J. Clin. Endocrinol. Metab. 2019, 104, 1595–1622.
[16]	Mori, T.; Crandall, C.J.; Ganz, D.A. Cost-effectiveness of combined oral bisphosphonate therapy and Falls prevention exercise for fracture prevention in the USA. Osteoporos. Int. 2017, 28, 585–595.
[17]	Mori, T.; Crandall, C.J.; Fujii, T.; Ganz, D.A. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. Arch. Osteoporos. 2021, 16, 113.
[18]	Li, N.N.; Cornelissen, D.; Silverman, S.; Pinto, D.; Si, L.; Kremer, I.; Bours, S.; de Bot, R.; Boonen, A.; Evers, S.; van den Bergh, J.; Reginster, J.Y.; Hiligsmann, M. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. PharmacoEconomics. 2021, 39, 181–209.
[19]	Cosman, F.; Nieves, J.W.; Dempster, D.W. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J. Bone Miner. Res. 2017, 32, 198–202.
[20]	Mori, T.; Crandall, C.J.; Fujii, T.; Ganz, D.A. Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Arch. Osteoporos. 2021, 16, 72.
[21]	Lv, F.B.; Yu, K.W.; Gao, W.W.; Yu, S.W. Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Chin. Pharm. Sci. 2017, 26, 447–454.
[22]	Chen, J.; Zhao L.B.; Wan Y.S.; Wang L.; Lv, Y.N.; Zhang, Y.; You, R.X. Rapid health technology assessment of treating osteoporosis with alendronate. Chin. J. Hospital Pharmacy. 2021, 41, 2227–2235.
[23]	Wang, H. Analysis on the principal component of the factors which effected medicine prices in China. Chin. Health Econ. 2018, 37, 71–73.
[24]	Luo, S.H.; Dong, L.L.; Li, Y.Y.; Xu, D.; Chen, M. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer. J. Chin. Pharm. Sci. 2021, 30, 253–263.